scholarly journals Clinical translation of theranostic radiopharmaceuticals: Current regulatory status and recent examples

2019 ◽  
Vol 62 (10) ◽  
pp. 673-683 ◽  
Author(s):  
Petra Kolenc Peitl ◽  
Christine Rangger ◽  
Piotr Garnuszek ◽  
Renata Mikolajczak ◽  
Alicja Hubalewska-Dydejczyk ◽  
...  
2020 ◽  
Vol 21 (11) ◽  
pp. 885-901
Author(s):  
Shubham Thakur ◽  
Amrinder Singh ◽  
Ritika Sharma ◽  
Rohan Aurora ◽  
Subheet Kumar Jain

Background: Surfactants are an important category of additives that are used widely in most of the formulations as solubilizers, stabilizers, and emulsifiers. Current drug delivery systems comprise of numerous synthetic surfactants (such as Cremophor EL, polysorbate 80, Transcutol-P), which are associated with several side effects though used in many formulations. Therefore, to attenuate the problems associated with conventional surfactants, a new generation of surface-active agents is obtained from the metabolites of fungi, yeast, and bacteria, which are termed as biosurfactants. Objectives: In this article, we critically analyze the different types of biosurfactants, their origin along with their chemical and physical properties, advantages, drawbacks, regulatory status, and detailed pharmaceutical applications. Methods: 243 papers were reviewed and included in this review. Results: Briefly, Biosurfactants are classified as glycolipids, rhamnolipids, sophorolipids, trehalolipids, surfactin, lipopeptides & lipoproteins, lichenysin, fatty acids, phospholipids, and polymeric biosurfactants. These are amphiphilic biomolecules with lipophilic and hydrophilic ends and are used as drug delivery vehicles (foaming, solubilizer, detergent, and emulsifier) in the pharmaceutical industry. Despite additives, they have some biological activity as well (anti-cancer, anti-viral, anti-microbial, P-gp inhibition, etc.). These biomolecules possess better safety profiles and are biocompatible, biodegradable, and specific at different temperatures. Conclusion: Biosurfactants exhibit good biomedicine and additive properties that can be used in developing novel drug delivery systems. However, more research should be driven due to the lack of comprehensive toxicity testing and high production cost which limits their use.


Author(s):  
Md Abul Barkat ◽  
Anjali Goyal ◽  
Harshita Abul Barkat ◽  
Mohammad Salauddin ◽  
Faheem Hyder Pottoo ◽  
...  

Abstract:: Herbal medicines pays an important in treating the vaious diseases mainly due to the their potentially high therapeutic values and also due to the better acceptance of vaioruspatient under different health complications. The herbal medicine practice involves use of part of plant, entire plant or the selectctive isolated phytomedicineand the use and practices based on these has its pros and cons and has been greatly affected during the dawn. The search of new drugs during scientific era revives the interest in discovery of herbal drugs from different natural resources during 20th century. The present modern healthcare system invovlves utilization drugs and 50% of them are of ofnaural origin. Herbal drug disocovery found to be highly costly affair with low success rate and it hinders the further progress in utilizting the phytomedicine in treating the various deseases. But in recent years there is an increase in the search interest of herbal drugs mainly by the pharmaceutical industry and those invoves in the search of novel drugs from the herbs. Discovery of such new novel phytomedicines has to overcomes various challenges in indentification of active extracts and their toxicity, advereffects, herb drug interaction and importantly their regulatory requirments. The present review mainly focused on the history of herbal medicine, current clinical perspective, pharmaceutical, and regulatory challenges as well as its clinical presentation. Moreover, problems encountered in drug discovery from herbal resources and its possible solutions are delineated.


2009 ◽  
Vol 9 (2) ◽  
pp. 83-90 ◽  
Author(s):  
Frank Jacobs ◽  
Yingmei Feng ◽  
Eline Craeyveld ◽  
Joke Lievens ◽  
Jan Snoeys ◽  
...  

2018 ◽  
Vol 6 (1) ◽  
pp. 64 ◽  
Author(s):  
Rodrigo De Vecchi ◽  
Vanja Dakic ◽  
Guilherme Mattos ◽  
Anne-Sophie Rigaudeau ◽  
Veronica Oliveira ◽  
...  

MedChemComm ◽  
2019 ◽  
Vol 10 (12) ◽  
pp. 2111-2117 ◽  
Author(s):  
Kusum Vats ◽  
Kanhaiyalal Agrawal ◽  
Rohit Sharma ◽  
Haladhar Dev Sarma ◽  
Drishty Satpati ◽  
...  

This study explores the feasibility of radiolabeling the HBED-CC-PSMA (PSMA-11) ligand with Tc-99m for SPECT imaging of prostate cancer patients.


2018 ◽  
Vol 5 ◽  
Author(s):  
Cameron Keighron ◽  
Caomhán J. Lyons ◽  
Michael Creane ◽  
Timothy O'Brien ◽  
Aaron Liew

2021 ◽  
Vol 5 (2) ◽  
pp. 021503
Author(s):  
Muhammad Anwaar Nazeer ◽  
Ismail Can Karaoglu ◽  
Onur Ozer ◽  
Cem Albayrak ◽  
Seda Kizilel

2021 ◽  
Vol 22 ◽  
pp. 100264
Author(s):  
Qian Chen ◽  
Wei Qin ◽  
Weizhi Qi ◽  
Lei Xi

Neurosurgery ◽  
2020 ◽  
Author(s):  
Ben Jiahe Gu ◽  
David K Kung ◽  
Han-Chiao Isaac Chen

Abstract Cell therapy has been widely recognized as a promising strategy to enhance recovery in stroke survivors. However, despite an abundance of encouraging preclinical data, successful clinical translation remains elusive. As the field continues to advance, it is important to reexamine prior clinical trials in the context of their intended mechanisms, as this can inform future preclinical and translational efforts. In the present work, we review the major clinical trials of cell therapy for stroke and highlight a mechanistic shift between the earliest studies, which aimed to replace dead and damaged neurons, and later ones that focused on exploiting the various neuromodulatory effects afforded by stem cells. We discuss why both mechanisms are worth pursuing and emphasize the means through which cell replacement can still be achieved.


Sign in / Sign up

Export Citation Format

Share Document